

10/524,060

sw
6-12-07

[0027] Figures 3A-G illustrate sA β -induced GRK5 translocation from membrane to cytosol in microglia;

[0028] Figures 4A-B illustrate inhibition of GRK-PAR binding by sA β -pretreatment in microglial cells;

[0029] Figures 5A-^C~~B~~ illustrate that pretreatment with sA β resulted in prolonged thrombin signaling in microglial cells; and

[0030] Figures 6A-B illustrate sA β -induced microglial hyper-reactivity to GPCR activators.

DETAILED DESCRIPTION OF THE INVENTION

[0031] The present invention is based, at least in part, on the discovery that dysfunction of G-protein coupled receptor kinases (GRKs) particularly GRK2 and GRK5, occurs in brains with Alzheimer's disease.

[0032] AD is a neurodegenerative disorder, with prominent pathological features involving the abnormal accumulation of a small peptide, termed β -amyloid (A β). However, the pathogenetic mechanisms associated with the abnormal A β accumulation remain unclear, which has significantly hampered understanding of the prognosis, prophylaxis and